Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.

We previously demonstrated that HF10, which is a natural, non-engineered HSV-1, has potent oncolytic activity in the treatment of solid malignant tumors in vitro and in vivo [H. Takakuwa, F. Goshima, N. Nozawa, T. Yoshikawa, H. Kimata, A. Nakao, et al., Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice, Arch. Virol. 148 (2003) 813-825; S. Kohno, C. Lou, F. Goshima, Y. Nishiyama, T. Sata, Y. Ono, Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer, Urology 66 (2005) 1116-1121; D. Watanabe, F. Goshima, I. Mori, Y. Tamada, Y. Matsumoto, Y. Nishiyama, Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10, J. Dermatol. Sci. 50 (2008) 185-196; A. Nawa, C. Luo, L. Zhang, Y. Ushijima, D. Ishida, M. Kamakura, et al., Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF10: applications for cancer gene therapy, Curr. Gene. Ther. 8 (2008) 208-221]. Previous reports have also shown that a combination of HF10 and paclitaxel (TAX) was more efficacious than either regimen alone for some types of malignant tumors [S. Shimoyama, F. Goshima, O. Teshigahara, H. Kasuya, Y. Kodera, A. Nakao, et al., Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models, Hepatogastroenterology 54 (2007) 1038-1042]. In this study, we investigated the efficacy of gene-directed enzyme prodrug therapy (GDEPT) using a novel system that combines the paclitaxel-2'-ethylcarbonate prodrug (TAX-2'-Et) and an HSV amplicon expressing rabbit-carboxylesterase (CES) with HF10 as a helper virus. This GDEPT system aims to produce high level of CES at the tumor site, resulting in efficient local conversion of the TAX-2'-Et prodrug into the active drug TAX [A. Nawa, T. Tanino, C. Lou, M. Iwaki, H. Kajiyama, K. Shibata, et al., Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?, Anti-Cancer Agents Med Chem 8 (2008) 232-239]. We demonstrated that the green fluorescent protein (GFP) gene, as a trace maker, was more efficiently introduced by the HSV amplicon compared to the expression vector, pHGCX, and that the HSV amplicon system expressed an active CES enzyme that could convert TAX-2'-Et to TAX in Cos7 cells. Furthermore, although the cytotoxicity of this amplicon system was not enhanced in virus-sensitive tumor cells, it was significantly enhanced in low virus-sensitive tumor cells in the presence of the prodrug in a concentration-dependent manner, compared to the control virus alone (p<0.05). These results indicate that the addition of a prodrug converting enzyme may be a feasible approach to further enhance the efficacy of HF10 as a cancer therapeutics in low HF10-sensitive malignancies.

[1]  M. Wierdl,et al.  Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. , 2001, Cancer research.

[2]  C. Springer,et al.  Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. , 2005, Cancer research.

[3]  C. Fraefel,et al.  HSV-1 amplicon vectors--simplicity and versatility. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  C. Morton,et al.  Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). , 1998, Cancer research.

[5]  I. Mori,et al.  Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. , 2008, Journal of dermatological science.

[6]  K. Delman,et al.  Functional Interaction between Fluorodeoxyuridine-Induced Cellular Alterations and Replication of a Ribonucleotide Reductase-Negative Herpes Simplex Virus , 2001, Journal of Virology.

[7]  T. Yoshikawa,et al.  Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice , 2003, Archives of Virology.

[8]  R. Jain,et al.  Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. , 2008, Cancer research.

[9]  P. Houghton,et al.  Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  M. Markman.  Taxanes in the management of gynecologic malignancies , 2008, Expert review of anticancer therapy.

[11]  X. Breakefield,et al.  Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  M. Dolan,et al.  Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. , 2000, Cancer research.

[13]  J. Armand,et al.  Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  M. Wierdl,et al.  Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. , 2000, Cancer research.

[15]  W. Mcguire.  Current status of taxane and platinum-based chemotherapy in ovarian cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Martuza,et al.  Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. , 2006, Journal of the National Cancer Institute.

[17]  A. Kudoh,et al.  Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10. , 2006, Journal of virological methods.

[18]  S. Guichard,et al.  Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity , 2000, Anti-cancer drugs.

[19]  E. Chiocca,et al.  Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. , 2001, Cancer research.

[20]  L. Pomeranz,et al.  Microtubule Reorganization during Herpes Simplex Virus Type 1 Infection Facilitates the Nuclear Localization of VP22, a Major Virion Tegument Protein , 2001, Journal of Virology.

[21]  T. Imai,et al.  Pilot Study of Oncolytic Viral Therapy Using Mutant Herpes Simplex Virus (HF10) Against Recurrent Metastatic Breast Cancer , 2006, Annals of surgical oncology.

[22]  M. Wierdl,et al.  Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. , 2003, Molecular pharmacology.

[23]  R. Spaete,et al.  The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector , 1982, Cell.

[24]  C. Morton,et al.  Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application. , 2004, Molecular cancer therapeutics.

[25]  E. Chiocca,et al.  Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. , 2005, Cancer research.

[26]  X. Breakefield,et al.  Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle. , 2002, Human gene therapy.

[27]  F. Kruyt,et al.  Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. , 2003, Molecular cancer therapeutics.

[28]  Y. Kodera,et al.  Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models. , 2007, Hepato-gastroenterology.

[29]  N. F. Magri,et al.  Modified taxols. 2. Oxidation products of taxol , 1986 .

[30]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[31]  A. Nakao,et al.  Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses. , 2003, Hepato-gastroenterology.

[32]  T. Pawlik,et al.  Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene , 2002, Cancer.

[33]  T. Chou,et al.  Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer , 2008, Clinical Cancer Research.

[34]  T. Imai,et al.  Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  T. Chou,et al.  5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer , 2005, Journal of Gastrointestinal Surgery.

[36]  Y. Nishiyama,et al.  Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma , 2006, Acta oto-laryngologica.

[37]  D. Kirn,et al.  Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. , 2007, Cancer research.

[38]  Y. Nishiyama,et al.  Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer. , 2005, Urology.

[39]  T. Pawlik,et al.  Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. , 2001, Cancer research.

[40]  Prasad Adusumilli,et al.  Up‐regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a γ134.5 deleted oncolytic herpes virus (G207) , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  L. Johnson,et al.  A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. , 2003, Cancer research.

[42]  C. Fairchild,et al.  Synthesis and antitumor evaluation of 2′-oxycarbonylpaclitaxels (paclitaxel-2′-carbonates) , 1994 .

[43]  E. Kondo,et al.  Paclitaxel-2′-Ethylcarbonate Prodrug Can Circumvent P-glycoprotein-mediated Cellular Efflux to Increase Drug Cytotoxicity , 2007, Pharmaceutical Research.